Adaptive Biotechnologies (ADPT) COO exercises options and sells 38K shares

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Adaptive Biotechnologies President and COO Julie Rubinstein exercised stock options and sold shares in pre-planned transactions. She exercised options to acquire 29,444 shares of common stock at $7.27 per share, then sold 38,120 shares of common stock in open-market trades at weighted average prices of $14.45 and $14.60 per share.

All transactions were effected under a Rule 10b5-1 trading plan adopted on November 18, 2025, indicating they were pre-scheduled. Following these trades, Rubinstein directly holds 447,202 shares of Adaptive Biotechnologies common stock.

Insider Trade Summary 10b5-1

Net Seller: 38,120 shares ($553,693)

Net Sell 6 txns

Insider RUBINSTEIN JULIE

Role President and COO

Sold 38,120 shs ($554K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	14,722	$0.00	--
Exercise	Common Stock	14,722	$7.27	$107K
Sale	Common Stock	19,060	$14.60	$278K
Exercise	Stock Option (right to buy)	14,722	$0.00	--
Exercise	Common Stock	14,722	$7.27	$107K
Sale	Common Stock	19,060	$14.45	$275K

Holdings After Transaction: Stock Option (right to buy) — 81,719 shares (Direct); Common Stock — 466,262 shares (Direct)

Footnotes (1)

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.66, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The option is fully vested and exercisable.

Key Figures

Options exercised: 29,444 shares Exercise price: $7.27/share Shares sold: 38,120 shares +4 more

7 metrics

Options exercised 29,444 shares Common stock acquired via option exercises at $7.27

Exercise price $7.27/share Stock Option (right to buy) for common stock

Shares sold 38,120 shares Open-market sales of common stock across two days

Sale price 1 $14.45/share Weighted average price for 19,060 shares sold on April 1

Sale price 2 $14.60/share Weighted average price for 19,060 shares sold on April 2

Post-trade holdings 447,202 shares Common stock directly held after all reported transactions

Remaining options 81,719 options Stock options remaining after exercises, expiring February 7, 2029

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (right to buy), fully vested and exercisable, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

fully vested and exercisable financial

"The option is fully vested and exercisable."

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

04/02/2026 - 07:16 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RUBINSTEIN JULIE

(Last)

(First)

(Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE

WASHINGTON

98109

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/01/2026		M⁽¹⁾		14,722	A	$7.27	470,600	D
Common Stock	04/01/2026		S⁽¹⁾		19,060	D	$14.45⁽²⁾	451,540	D
Common Stock	04/02/2026		M⁽¹⁾		14,722	A	$7.27	466,262	D
Common Stock	04/02/2026		S⁽¹⁾		19,060	D	$14.6⁽³⁾	447,202	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$7.27	04/01/2026		M⁽¹⁾			14,722	⁽⁴⁾	02/07/2029	Common Stock	14,722	$0	96,441	D
Stock Option (right to buy)	$7.27	04/02/2026		M⁽¹⁾			14,722	⁽⁴⁾	02/07/2029	Common Stock	14,722	$0	81,719	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.66, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

4. The option is fully vested and exercisable.

	/s/ Julie Rubinstein by Kyle Piskel, Attorney-in-Fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did ADPT President and COO Julie Rubinstein report?

Julie Rubinstein reported exercising options for 29,444 shares at $7.27 and selling 38,120 common shares in open-market trades. These transactions were routine equity compensation exercises combined with partial share sales rather than new open-market share purchases.

At what prices did Julie Rubinstein sell Adaptive Biotechnologies (ADPT) shares?

Rubinstein sold 19,060 shares at a weighted average of $14.45 and another 19,060 shares at a weighted average of $14.60. Footnotes state each block was executed in multiple trades within price ranges around those averages.

How many Adaptive Biotechnologies (ADPT) shares does Julie Rubinstein hold after these trades?

After the reported transactions, Julie Rubinstein directly holds 447,202 shares of Adaptive Biotechnologies common stock. This figure reflects her position after exercising options and completing the two open‑market sale transactions disclosed in the Form 4.

Were Julie Rubinstein’s ADPT stock sales under a Rule 10b5-1 trading plan?

Yes. A footnote states that all transactions in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2025. Such plans pre-schedule trades, reducing the significance of short-term market timing.

What stock options did Julie Rubinstein exercise in this ADPT Form 4?

Rubinstein exercised stock options labeled as a “Stock Option (right to buy)” for 14,722 shares on each of two dates, totaling 29,444 shares, at an exercise price of $7.27 per share. A footnote notes that the option is fully vested and exercisable.

Does this ADPT Form 4 show remaining option holdings for Julie Rubinstein?

Yes. After the option exercises, one derivative entry shows 81,719 stock options following the transaction, with an expiration date of February 7, 2029. This indicates Rubinstein continues to hold a meaningful remaining option position beyond the shares just exercised.